Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer
Journal of the National Comprehensive Cancer Network · 2024-06 · 22 (2D)
DOI: 10.6004/jnccn.2023.7331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024-06. Verfasst von Ranjit Manchanda und 31 weiteren Autor:innen. Beteiligte Einrichtung: 1Wolfson Institute of Population Health, CRUK Barts Cancer Centre, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Genetic Testing, Germ-Line Mutation, Carcinoma, Ovarian Epithelial. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 79 Literaturangaben.
Abstract (Originalsprache)
Background
Parallel panel germline and somatic genetic testing of all patients with ovarian cancer (OC) can identify more pathogenic variants (PVs) that would benefit from PARP inhibitor (PARPi) therapy, and allow for precision prevention in unaffected relatives with PVs. In this study, we estimate the cost-effectiveness and population impact of parallel panel germline and somatic BRCA testing of all patients with OC incorporating PARPi therapy in the United Kingdom and the United States compared with clinical criteria/family history (FH)–based germline BRCA testing. We also evaluate the cost-effectiveness of multigene panel germline testing alone.
Methods
Microsimulation cost-effectiveness modeling using data from 2,391 (UK: n=1,483; US: n=908) unselected, population-based patients with OC was used to compare lifetime costs and effects of panel germline and somatic BRCA testing of all OC cases (with PARPi therapy) (strategy A) versus clinical criteria/FH-based germline BRCA testing (strategy B). Unaffected relatives with germline BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 PVs identified through cascade testing underwent appropriate OC and breast cancer (BC) risk-reduction interventions. We also compared the cost-effectiveness of multigene panel germline testing alone (without PARPi therapy) versus strategy B. Unaffected relatives with PVs could undergo risk-reducing interventions. Lifetime horizon with payer/societal perspectives, along with probabilistic/one-way sensitivity analyses, are presented. Incremental cost-effectiveness ratio (ICER) and incremental cost per quality-adjusted life year (QALY) gained were compared with £30,000/QALY (UK) and $100,000/QALY (US) thresholds. OC incidence, BC incidence, and prevented deaths were estimated.
Results
Compared with clinical criteria/FH-based BRCA testing, BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 germline testing and BRCA1/BRCA2 somatic testing of all patients with OC incorporating PARPi therapy had a UK ICER of £51,175/QALY (payer perspective) and £50,202/QALY (societal perspective) and a US ICER of $175,232/QALY (payer perspective) and $174,667/QALY (societal perspective), above UK/NICE and US cost-effectiveness thresholds in the base case. However, strategy A becomes cost-effective if PARPi costs decrease by 45% to 46% or if overall survival with PARPi reaches a hazard ratio of 0.28. Unselected panel germline testing alone (without PARPi therapy) is cost-effective, with payer-perspective ICERs of £11,291/QALY or $68,808/QALY and societal-perspective ICERs of £6,923/QALY or $65,786/QALY. One year’s testing could prevent 209 UK BC/OC cases and 192 deaths, and 560 US BC/OC cases and 460 deaths.
Conclusions
Unselected panel germline and somatic BRCA testing can become cost-effective, with a 45% to 46% reduction in PARPi costs. Regarding germline testing, unselected panel germline testing is highly cost-effective and should replace BRCA testing alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Wolfson Institute of Population Health, CRUK Barts Cancer Centre, Queen Mary University of London, London, UK.
- 2Department of Gynecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, UK.
- 3Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.
- 4MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, Faculty of Population Health Sciences, University College London, London, UK.
- 5Department of Gynecology, All India Institute of Medical Sciences, New Delhi, India.
- 6Division of Gynecology and Perinatology, University Medical Centre Maribor, Maribor, Slovenia.
Zitieren
APA
Manchanda, R., Sun, L., Sobocan, M., Rodriguez, I. V., Wei, X., Kalra, A., Oxley, S., Sideris, M., Fierheller, C. T., Morgan, R. D., Chandrasekaran, D., Rust, K., Spiliopoulou, P., Miller, R. E., Crusz, S. M., Lockley, M., Singh, N., Faruqi, A., Casey, L., …, & Legood, R. (2024). Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer. Journal of the National Comprehensive Cancer Network, 22(2D). https://doi.org/10.6004/jnccn.2023.7331
Vancouver
Manchanda R, Sun L, Sobocan M, Rodriguez IV, Wei X, Kalra A, et al. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer. Journal of the National Comprehensive Cancer Network. 2024;22(2D). doi:10.6004/jnccn.2023.7331
BibTeX
@article{Manchanda2024,
author = {Manchanda, Ranjit and Sun, Li and Sobocan, Monika and Rodriguez, Isabel V and Wei, Xia and Kalra, Ashwin and Oxley, Samuel and Sideris, Michail and Fierheller, Caitlin T and Morgan, Robert D and Chandrasekaran, Dhivya and Rust, Kelly and Spiliopoulou, Pavlina and Miller, Rowan E and Crusz, Shanthini M and Lockley, Michelle and Singh, Naveena and Faruqi, Asma and Casey, Laura and Brockbank, Elly and Phadnis, Saurabh and Mills-Baldock, Tina and El-Khouly, Fatima and Jenkins, Lucy A and Wallace, Andrew and Ahmed, Munaza and Kumar, Ajith and Swisher, Elizabeth M and Gourley, Charlie and Norquist, Barbara M and Evans, D Gareth and Legood, Rosa},
title = {Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2024},
volume = {22},
number = {2D},
doi = {10.6004/jnccn.2023.7331}
}
EUVIMED